Mucolytic Medications for Respiratory Conditions

Classification and Mechanism of Mucoactive Agents

Mucolytics, such as N-acetylcysteine (NAC) and erdosteine, decrease mucus viscosity by breaking disulfide bonds in mucoproteins, and are used to improve clearance from the respiratory tract in patients with chronic respiratory conditions 1
Mucoregulators, including carbocisteine, regulate mucus secretion and are used in the management of chronic respiratory conditions with excessive mucus, with moderate to high strength of evidence 1, 4
Mucokinetics, such as bronchodilators, increase mucociliary clearance and are used to improve respiratory function in patients with chronic respiratory conditions 1

N-acetylcysteine (NAC) reduces viscosity of respiratory secretions by cleaving disulfide bonds in mucoproteins, with high-dose therapy (600 mg twice daily) showing greater efficacy in reducing COPD exacerbations, and is generally well-tolerated with rare gastrointestinal side effects, according to the European Respiratory Society 4, 2
Carbocisteine regulates mucus secretion as a mucoregulator and may reduce exacerbations in patients with COPD, with moderate strength of evidence 1, 4
Erdosteine has mucolytic, anti-bacterial, anti-oxidant, and anti-inflammatory effects, and may improve spirometry and sputum clearance when combined with physiotherapy, although the strength of evidence is limited 1

Mucolytics, particularly NAC and carbocisteine, may reduce exacerbation frequency and hospitalization rates in patients with moderate to severe COPD, with moderate to high strength of evidence 4, 2
The European Respiratory Society suggests oral mucolytic therapy for patients with moderate or severe COPD and exacerbations despite optimal inhaled therapy, with high strength of evidence 4, 2
High-dose mucolytic therapy shows greater efficacy than lower doses in reducing exacerbations, with moderate strength of evidence 4, 2

Most clinical evidence supporting mucolytic use comes from studies with N-acetylcysteine rather than other agents, with high strength of evidence 3
Regular use of oral mucolytics is not routinely recommended for prevention of lower respiratory tract infections in patients with chronic bronchitis, COPD, or bronchiectasis, with moderate strength of evidence 5